Dennis Ding
Stock Analyst at Jefferies
(n/a)
# 4,538
Out of 4,843 analysts
11
Total ratings
n/a
Success rate
-25.73%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dennis Ding
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRNX Crinetics Pharmaceuticals | Upgrades: Buy | $55 | $30.51 | +80.27% | 1 | Jan 22, 2025 | |
| IKT Inhibikase Therapeutics | Initiates: Buy | $8 | $2.03 | +294.09% | 1 | Nov 8, 2024 | |
| ASMB Assembly Biosciences | Upgrades: Buy | $2 → $35 | $14.01 | +149.82% | 1 | Sep 20, 2024 | |
| FOLD Amicus Therapeutics | Initiates: Buy | $18 | $6.07 | +196.54% | 1 | Sep 6, 2024 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $5 → $7 | $3.36 | +108.33% | 2 | Sep 5, 2024 | |
| RXRX Recursion Pharmaceuticals | Maintains: Hold | $8 → $6 | $4.18 | +43.54% | 1 | Sep 3, 2024 | |
| LYRA Lyra Therapeutics | Downgrades: Hold | $10 → $0.5 | $4.93 | -89.86% | 1 | May 7, 2024 | |
| CORT Corcept Therapeutics | Downgrades: Hold | $35 → $22 | $77.56 | -71.63% | 1 | Feb 15, 2023 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Buy | $24 | $18.11 | +32.52% | 1 | Dec 19, 2022 | |
| ROIV Roivant Sciences | Initiates: Buy | $10 | $10.99 | -9.01% | 1 | Oct 26, 2021 |
Crinetics Pharmaceuticals
Jan 22, 2025
Upgrades: Buy
Price Target: $55
Current: $30.51
Upside: +80.27%
Inhibikase Therapeutics
Nov 8, 2024
Initiates: Buy
Price Target: $8
Current: $2.03
Upside: +294.09%
Assembly Biosciences
Sep 20, 2024
Upgrades: Buy
Price Target: $2 → $35
Current: $14.01
Upside: +149.82%
Amicus Therapeutics
Sep 6, 2024
Initiates: Buy
Price Target: $18
Current: $6.07
Upside: +196.54%
Arbutus Biopharma
Sep 5, 2024
Maintains: Buy
Price Target: $5 → $7
Current: $3.36
Upside: +108.33%
Recursion Pharmaceuticals
Sep 3, 2024
Maintains: Hold
Price Target: $8 → $6
Current: $4.18
Upside: +43.54%
Lyra Therapeutics
May 7, 2024
Downgrades: Hold
Price Target: $10 → $0.5
Current: $4.93
Upside: -89.86%
Corcept Therapeutics
Feb 15, 2023
Downgrades: Hold
Price Target: $35 → $22
Current: $77.56
Upside: -71.63%
NewAmsterdam Pharma Company
Dec 19, 2022
Initiates: Buy
Price Target: $24
Current: $18.11
Upside: +32.52%
Roivant Sciences
Oct 26, 2021
Initiates: Buy
Price Target: $10
Current: $10.99
Upside: -9.01%